# Lapatinib in Combination With Vinorelbine

> **NCT01013740** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 112 (actual)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** Vinorelbine
- **DRUG:** Lapatinib
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT01013740
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11-25
- **Primary completion:** 2012-08-21
- **Final completion:** 2016-03-01
- **Target enrollment:** 112 (ACTUAL)
- **Last updated:** 2017-05-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01013740

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01013740, "Lapatinib in Combination With Vinorelbine". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01013740. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*